Drug Trial Radar · NCT04402957
LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)
Last checked: Nov 19, 2026Latest source record: Jul 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
61
Actual
Start
Oct 14, 2020
Primary completion
May 27, 2021
Study completion Jun 2, 2022
Sponsor
- Lead sponsor
- Arch Biopartners Inc.Industry
- Sponsor type
- Industry
- First posted
- May 27, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the proportion of subjects alive and free of respiratory failure (e.g. need for non-invasive or invasive mechanical ventilation, high flow oxygen, or ECMO) and free of the need for continued renal replacement therapy (RRT) on Day 28. The need for continued RRT at Day 28 will be defined as either dialysis in the past 3 days (Day 26, 27, or 28) or an eGFR on Day 28 \<10 mL/min/1.73 m2.
Conditions
- COVID
- Severe Acute Respiratory Syndrome
- Sars-CoV2
- Acute Kidney Injury
- Acute Respiratory Distress Syndrome
Interventions
LSALT peptideDrug
LSALT, a peptide drug with the sequence NH3-LSALTPSPSWLKYKAL-COOH, binds to dipeptidase-1 (DPEP-1) but does not inhibit its biologic enzymatic activity. LSALT peptide inhibits leukocyte recruitment in multiple experimental disease models through the direct inhibition of leukocyte adhesion to DPEP-1 present in lungs, kidney, and liver.
PlaceboDrug
0.9% saline solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- To Evaluate the Proportion of Subjects Alive and Free of Respiratory Failure and Free of the Need for Continued Renal Replacement Therapy (RRT) on Day 28 (as Per Protocol AB002 - Version 1, Dated 09JUNE2020)Time frame: 28 days
Locations
7 sites in 3 countries. Site status is shown where the registry gives one.
VA San Diego Healthcare System
San Diego, California
Broward Health Medical Center
Fort Lauderdale, Florida
LSU Health Shreveport
Shreveport, Louisiana
University of Calgary - Foothills Medical Centre
Calgary, Alberta, Canada
University of Calgary - Peter Lougheed Centre
Calgary, Alberta, Canada
Ankara City Hospital
Ankara, Turkey (Türkiye)
Istanbul University Cerrahpasa
Istanbul, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.